pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
The biochemical mechanism of VOC generation in the human body is not fully comprehended. Their occurrence is due to changes in cell metabolism, inflammation, and oxidative stress, where reactive oxygen species (ROS) produced from cellular respiration interact with cellular structures (such as the membrane, proteins, DNA, and RNA) to create VOCs. The accumulation occurs in breath, skin, sweat, blood, urine, and faeces. The samples can be analyzed by various methods, such as selected-ion-flow-tube mass spectrometry (SIFT-MS), field asymmetric ion mobility spectrometry (FAIMS), nuclear magnetic resonance (NMR) spectroscopy, proton-transfer-reaction mass spectrometry (PTR-MS) and more, but the commonly used technologies are gas chromatography with mass spectrometry (GC-MS) and electric nose (e-nose). The difference in samples and methods of analysis chosen may explain the high heterogeneity observed in VOCs identified in different studies pertaining to the same diseases.
meaning one infectious person on average infects 0.4 susceptible people per day and recovers in 1/0.2=5 days. Thus when this person recovered, there are two people still infectious directly got from this person and
== Further reading == Hunt, Chris; et al. (August 28, 2023). "Shanidar et ses fleurs? Reflections on the palynology of the Neanderthal 'Flower Burial' hypothesis". Journal of Archaeological Science. 159 105822. Bibcode:2023JArSc.159j5822H. doi:10.1016/j.jas.2023.105822. S2CID 261325698. Pettitt, Paul; White, Mark (2012). The British Palaeolithic: hominin societies at the edge of the Pleistocene world. London: Routledge. ISBN 978-0-415-67454-6. Romagnoli, Francesca; Rivals, Florent; Benazzi, Stefano (2022). Updating Neanderthals: Understanding Behavioural Complexity in the Late Middle Palaeolithic. Academic Press. ISBN 978-0-12-821429-9. Stringer, C.; Gamble, C. (1993). In search of the Neanderthals. Thames and Hudson. ISBN 0-500-05070-8. Sykes, Rebecca Wragg (2020). Kindred: Neanderthal Life, Love, Death and Art. London: Bloomsbury Sigma. ISBN 978-1-4729-3749-0.
Sources: en.wikipedia.org
Third, Article 101 of the TFEU prohibits cartels or collusive practices, including competitors engaging in (a) price fixing, (b) limiting production, (c) sharing markets, (d) applying dissimilar conditions to equivalent transactions, and (e) making contracts subject to unconnected obligations. According to Article 101(2) any such agreements between undertakings are automatically void. Article 101(3) establishes exemptions, if the collusion is for distributional or technological innovation, gives consumers a "fair share" of the benefit and does not include unreasonable restraints that risk eliminating competition anywhere. For example, in Parker ITR Srl v Commission eleven corporations that manufactured marine hoses for offshore oil rigs were fined €131 million for rigging bids and sharing markets worldwide – they would designate a "bid champion" in each case to raise prices. Secret cartels are often hard to prove, so the courts allow competition regulators to establish collusion where there is no other plausible explanation for price rises. Some agreements among businesses, however, can be highly beneficial. For instance, in a decision on the Conseil Européen de la Construction d'Appareils Domestiques, the Commission held an agreement among washing machine makers to phase out production of low-efficiency machines was lawful, especially since it would lead to "reduced pollution from electricity generation".
In human adult females, the primordial follicle is composed of a single oocyte surrounded by a layer of closely associated granulosa cells. In early stages of the ovarian cycle, the developing follicle acquires a layer of connective tissue and associated blood vessels. This covering is called the theca. As development of the secondary follicle progresses, granulosa cells proliferate to form the multilayered membrana granulosum. Over a period of months, the granulosa cells and thecal cells secrete follicular fluid (a mixture of hormones, enzymes, and anticoagulants) to nourish the maturing ovum. In tertiary follicles, the single-layered theca differentiates into a theca interna and theca externa. The theca interna contains glandular cells and many small blood vessels, while the theca externa is composed of dense connective tissue and larger blood vessels.
== Research and advocacy == The Muscular Dystrophy Association (MDA) is involved in research, advocacy, and services for individuals affected by muscular dystrophy. The organization provides resources that contribute to understanding and addressing this condition.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.